MAPS Drug Utilization Reports offer data regarding controlled substance prescriptions dispensed in Michigan. In 2019, the number of opioid prescriptions dispensed decreased by 30.7 percent since 2015. Effective January 4, 2019, gabapentin was classified as a Schedule 5 controlled substance and accounts for 2,271,317 (12.3%) of all 2019 controlled substance prescriptions reported to MAPS.
Total CS prescriptions dispensed |
% change from previous year |
|
2007 |
17,007,858 |
|
2008 |
17,400,640 |
2.31% |
2009 |
17,876,684 |
2.74% |
2010 |
18,954,172 |
6.03% |
2011 |
19,763,680 |
4.27% |
2012 |
20,991,020 |
6.21% |
2013 |
20,728,216 |
-1.25% |
2014 |
20,904,764 |
0.85% |
2015 |
21,472,326 |
2.71% |
2016 |
21,092,674 |
-1.77% |
2017 | 19,943,203 | -5.45% |
2018 (updated Nov 5, 2019) |
17,623,754 |
-11.63% |
2019 | 18,472,677 | 4.82% |
2007 | 2008 |
2009 | 2010 |
2011 | 2012 |
2013 | 2014 |
2015 | 2016 |
2017 | 2018 (Updated Nov 5, 2019) |
2019 |
A new statewide assessment has identified trends that will assist government agencies, lawmakers and local community leaders tailor laws, target resources, and design innovative programs to best address the opioid epidemic in Michigan.
The assessment overlays three years (2013-2015) of well-documented cases of unintentional overdose death with five years (2012-2017) of prescription records in the Michigan Automated Prescription System (MAPS). In total, more than 7.5 million patients receiving 103.2 million prescriptions over the last five years were linked to 5,261 overdose deaths.
The assessment provides valuable information about patterns of opioid usage in Michigan by detailing patient-level and aggregate trends of controlled-substance prescriptions and overdose deaths within the state.
A new study, the Michigan AWARxE/NarxCare Implementation Evaluation, is the nation’s first study evaluating the effectiveness of NarxCare. Appriss’s Michigan Implementation and Evaluation analyzes NarxCare risk scores and shows a decline in patients with a high potential to abuse prescription drugs.
Telephone: 517-241-0166
Fax: 517-241-5072
Email: BPL-MAPS@michigan.gov
The State of Michigan is covering the full cost of integration of MAPS into the clinical workflow of health systems, physician groups and pharmacies until August 31, 2020. Learn how to start the integration process.
If your question(s) pertain to the new opioid legislation, we encourage you to review the recently-released FAQs. Additional questions or concerns can be addressed by contacting MAPS.